Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Pathophysiology of hepatitis C virus infection and related liver disease.

Pawlotsky JM.

Trends Microbiol. 2004 Feb;12(2):96-102. Review.

PMID:
15036326
2.

Telaprevir for previously untreated chronic hepatitis C virus infection.

Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team.

N Engl J Med. 2011 Jun 23;364(25):2405-16. doi: 10.1056/NEJMoa1012912.

3.

Factors that predict response of patients with hepatitis C virus infection to boceprevir.

Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators.

Gastroenterology. 2012 Sep;143(3):608-618.e5. doi: 10.1053/j.gastro.2012.05.011. Epub 2012 May 21.

PMID:
22626609
4.

Antiviral strategies in hepatitis C virus infection.

Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM.

J Hepatol. 2012;56 Suppl 1:S88-100. doi: 10.1016/S0168-8278(12)60010-5. Review.

PMID:
22300469
5.

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.

Welsch C, Jesudian A, Zeuzem S, Jacobson I.

Gut. 2012 May;61 Suppl 1:i36-46. doi: 10.1136/gutjnl-2012-302144. Review. Erratum in: Gut. 2012 Aug;61(8):1145.

PMID:
22504918
6.

Response-guided telaprevir combination treatment for hepatitis C virus infection.

Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F; ILLUMINATE Study Team.

N Engl J Med. 2011 Sep 15;365(11):1014-24. doi: 10.1056/NEJMoa1014463. Erratum in: N Engl J Med. 2011 Oct 20;365(16):1551.

7.

Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.

Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL.

Nat Med. 2012 Jan 8;18(2):281-5. doi: 10.1038/nm.2581.

8.

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ.

Ann Intern Med. 2006 May 16;144(10):705-14.

PMID:
16702586
9.

Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office.

Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A; Department of Veterans Affairs Hepatitis C Resource Center Program; National Hepatitis C Program Office.

Am J Gastroenterol. 2012 May;107(5):669-89; quiz 690. doi: 10.1038/ajg.2012.48.

PMID:
22525303
10.

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases.

Hepatology. 2011 Oct;54(4):1433-44. doi: 10.1002/hep.24641. Epub 2011 Sep 26. No abstract available.

11.

Advances in the treatment of hepatitis C virus infection.

Thomas DL.

Top Antivir Med. 2012 Apr-May;20(1):5-10.

12.

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M.

Nature. 2009 Oct 8;461(7265):798-801. doi: 10.1038/nature08463.

13.

Correlation between fibroscan, liver biopsy, and clinical liver function in patients with hepatitis C virus infection after renal transplantation.

Muñoz R, Ramírez E, Fernandez I, Martin A, Romero M, Romero E, Dominguez-Gil B, Hernandez A, Morales E, Andres A, Castellano G, Morales JM.

Transplant Proc. 2009 Jul-Aug;41(6):2425-6. doi: 10.1016/j.transproceed.2009.06.103.

PMID:
19715940
14.

Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.

Barritt AS 4th, Fried MW.

Gastroenterology. 2012 May;142(6):1314-1323.e1. doi: 10.1053/j.gastro.2012.02.013. Review.

15.

Cancer stem cells generated by alcohol, diabetes, and hepatitis C virus.

Machida K, Chen CL, Liu JC, Kashiwabara C, Feldman D, French SW, Sher L, Hyeongnam JJ, Tsukamoto H.

J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2:19-22. doi: 10.1111/j.1440-1746.2011.07010.x. Review.

16.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J.

N Engl J Med. 2002 Sep 26;347(13):975-82.

17.

New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets.

Ploss A, Dubuisson J.

Gut. 2012 May;61 Suppl 1:i25-35. doi: 10.1136/gutjnl-2012-302048. Review.

PMID:
22504917
18.

AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection.

Sheth SG, Flamm SL, Gordon FD, Chopra S.

Am J Gastroenterol. 1998 Jan;93(1):44-8.

PMID:
9448172
19.

2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.

European Association of the Study of the Liver.

Liver Int. 2012 Feb;32 Suppl 1:2-8. doi: 10.1111/j.1478-3231.2011.02703.x. Review.

PMID:
22212565
20.

A genetically humanized mouse model for hepatitis C virus infection.

Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A.

Nature. 2011 Jun 8;474(7350):208-11. doi: 10.1038/nature10168.

Supplemental Content

Support Center